Literature DB >> 23807289

Endothelial activation and inflammation biomarkers in children and adolescents with sickle cell disease.

Emmanuil S Hatzipantelis1, Zoe Dorothea Pana, N Gombakis, A Taparkou, V Tzimouli, D Kleta, D J Zafeiriou, V Garipidou, F Kanakoudi, M Athanassiou.   

Abstract

Sickle cell disease pathogenesis is a complex interplay of multiple factors associated with vascular endothelial activation, intense oxidative stress, and increased sickle cell adhesion. The aim of this study was to determine and compare three panels of plasma circulating biomarkers at 'steady state' and during veno-occlusive crises (VOC) in a cohort of children and adolescents with SCD and healthy controls. The following biomarkers were assessed: acute phase reactants, endothelial factors, and adhesion molecules. Forty-one SCD pediatric patients and 28 healthy children were enrolled. Patients at 'steady state' presented significantly elevated plasma levels of endothelin-1 (ET-1), soluble-VCAM-1 (sVCAM-1), soluble P-selectin (sP-selectin), and d-dimers compared to the control group. ET-1, sP-selectin, platelet-derived growth factor (PDGF), von Willebrand factor (vWf), d-dimers, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) seems to represent additional, but not independent, prognostic markers of VOC crisis. Elevated plasma levels of sP-selectin, ET-1, and sVCAM-1 were associated with VOC frequency. The present study provides preliminary evidence of a possible association between these biomarkers and the endothelial activation at steady state and VOC in childhood SCD. Further prospective studies are required to confirm the potential independent prognostic value of these markers in different stages of pediatric SCD.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23807289     DOI: 10.1007/s12185-013-1392-y

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  20 in total

1.  Endothelial function in patients with sickle cell anemia during and after sickle cell crises.

Authors:  Arnon Blum; Shay Yeganeh; Aviva Peleg; Fina Vigder; Konstantin Kryuger; Ahmed Khatib; Khalid Khazim; Harold Dauerman
Journal:  J Thromb Thrombolysis       Date:  2005-04       Impact factor: 2.300

Review 2.  Sickle cell anemia and vascular dysfunction: the nitric oxide connection.

Authors:  Idowu Akinsheye; Elizabeth S Klings
Journal:  J Cell Physiol       Date:  2010-09       Impact factor: 6.384

3.  Lower airway nitric oxide is increased in children with sickle cell disease.

Authors:  Dhenuka K Radhakrishnan; Glenda N Bendiak; Dimas Mateos-Corral; Suhail Al-Saleh; Rakesh Bhattacharjee; Melanie Kirby-Allen; Hartmut Grasemann
Journal:  J Pediatr       Date:  2011-08-24       Impact factor: 4.406

4.  The metabolites of nitric oxide in sickle-cell disease.

Authors:  D C Rees; P Cervi; D Grimwade; A O'Driscoll; M Hamilton; N E Parker; J B Porter
Journal:  Br J Haematol       Date:  1995-12       Impact factor: 6.998

5.  Patterns of arginine and nitric oxide in patients with sickle cell disease with vaso-occlusive crisis and acute chest syndrome.

Authors:  C R Morris; F A Kuypers; S Larkin; E P Vichinsky; L A Styles
Journal:  J Pediatr Hematol Oncol       Date:  2000 Nov-Dec       Impact factor: 1.289

6.  Divergent nitric oxide bioavailability in men and women with sickle cell disease.

Authors:  Mark T Gladwin; Alan N Schechter; Frederick P Ognibene; Wynona A Coles; Christopher D Reiter; William H Schenke; Gyorgy Csako; Myron A Waclawiw; Julio A Panza; Richard O Cannon
Journal:  Circulation       Date:  2003-01-21       Impact factor: 29.690

7.  Increased levels of the inflammatory biomarker C-reactive protein at baseline are associated with childhood sickle cell vasocclusive crises.

Authors:  Suba Krishnan; Yamaja Setty; Suhita G Betal; Vaidyula Vijender; Koneti Rao; Carlton Dampier; Marie Stuart
Journal:  Br J Haematol       Date:  2009-12-08       Impact factor: 6.998

8.  Coagulation activation and inflammation in sickle cell disease-associated pulmonary hypertension.

Authors:  Kenneth I Ataga; Charity G Moore; Cheryl A Hillery; Susan Jones; Herbert C Whinna; Dell Strayhorn; Cathy Sohier; Alan Hinderliter; Leslie V Parise; Eugene P Orringer
Journal:  Haematologica       Date:  2008-01       Impact factor: 9.941

9.  Vasculopathy in sickle cell disease: Biology, pathophysiology, genetics, translational medicine, and new research directions.

Authors:  Gregory J Kato; Robert P Hebbel; Martin H Steinberg; Mark T Gladwin
Journal:  Am J Hematol       Date:  2009-09       Impact factor: 10.047

Review 10.  Sickle red cell-endothelium interactions.

Authors:  Dhananjay K Kaul; Eileen Finnegan; Gilda A Barabino
Journal:  Microcirculation       Date:  2009-01       Impact factor: 2.628

View more
  15 in total

1.  Dietary ω-3 fatty acids protect against vasculopathy in a transgenic mouse model of sickle cell disease.

Authors:  Brian T Kalish; Alessandro Matte; Immacolata Andolfo; Achille Iolascon; Olga Weinberg; Alessandra Ghigo; James Cimino; Angela Siciliano; Emilio Hirsch; Enrica Federti; Mark Puder; Carlo Brugnara; Lucia De Franceschi
Journal:  Haematologica       Date:  2015-05-01       Impact factor: 9.941

2.  Elevated soluble platelet glycoprotein VI is a useful marker for DVT in postoperative patients treated with edoxaban.

Authors:  Takumi Aota; Katsuki Naitoh; Hideo Wada; Yoshiki Yamashita; Noriki Miyamoto; Masahiro Hasegawa; Hiroki Wakabayashi; Kakunoshin Yoshida; Kunihiro Asanuma; Takeshi Matsumoto; Kohshi Ohishi; Yuji Shimokariya; Norikazu Yamada; Masakatsu Nishikawa; Naoyuki Katayama; Atsumasa Uchida; Akihiro Sudo
Journal:  Int J Hematol       Date:  2014-09-25       Impact factor: 2.490

3.  Elevated D-dimer levels in African Americans with sickle cell trait.

Authors:  Rakhi P Naik; James G Wilson; Lynette Ekunwe; Stanford Mwasongwe; Qing Duan; Yun Li; Adolfo Correa; Alexander P Reiner
Journal:  Blood       Date:  2016-03-11       Impact factor: 22.113

4.  Simvastatin reduces vaso-occlusive pain in sickle cell anaemia: a pilot efficacy trial.

Authors:  Carolyn Hoppe; Eufemia Jacob; Lori Styles; Frans Kuypers; Sandra Larkin; Elliott Vichinsky
Journal:  Br J Haematol       Date:  2017-03-28       Impact factor: 6.998

Review 5.  Alteration of lymphocyte phenotype and function in sickle cell anemia: Implications for vaccine responses.

Authors:  Emmanuel Balandya; Teri Reynolds; Stephen Obaro; Julie Makani
Journal:  Am J Hematol       Date:  2016-07-14       Impact factor: 10.047

6.  Vascular Ehlers-Danlos syndrome: exploring the role of inflammation in arterial disease.

Authors:  Dianna M Milewicz; Amy J Reid; Alana C Cecchi
Journal:  Circ Cardiovasc Genet       Date:  2014-02

7.  Heme-bound iron activates placenta growth factor in erythroid cells via erythroid Krüppel-like factor.

Authors:  Xunde Wang; Laurel Mendelsohn; Heather Rogers; Susan Leitman; Nalini Raghavachari; Yanqin Yang; Yu Ying Yau; Michael Tallack; Andrew Perkins; James G Taylor; Constance Tom Noguchi; Gregory J Kato
Journal:  Blood       Date:  2014-06-10       Impact factor: 22.113

8.  Endothelin-1 contributes to the progression of renal injury in sickle cell disease via reactive oxygen species.

Authors:  J Brett Heimlich; Joshua S Speed; Paul M O'Connor; Jennifer S Pollock; Tim M Townes; Steffen E Meiler; Abdullah Kutlar; David M Pollock
Journal:  Br J Pharmacol       Date:  2016-01       Impact factor: 8.739

9.  The acute phase inflammatory response to maximal exercise testing in children and young adults with sickle cell anaemia.

Authors:  Robert I Liem; Kasiemobi Onyejekwe; Marie Olszewski; Chisalu Nchekwube; Frank P Zaldivar; Shlomit Radom-Aizik; Mark J Rodeghier; Alexis A Thompson
Journal:  Br J Haematol       Date:  2015-10-12       Impact factor: 6.998

Review 10.  Hydroxyurea therapy for priapism prevention and erectile function recovery in sickle cell disease: a case report and review of the literature.

Authors:  Uzoma A Anele; A Kyle Mack; Linda M S Resar; Arthur L Burnett
Journal:  Int Urol Nephrol       Date:  2014-05-14       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.